Alphari set to leave Misfits for Origen as Maxlore signs new deal

alphari leaves misfits for 1 1

British top-laner Barney “Alphari” Morris is joining Origen, according to the League of Legends global contract database and various reports.
He has signed a two-year deal with Origen, according to the database, ending November 17th 2020, and joins Origen’s other new signings Erlend “Nukeduck” Holm and Patrik “Sherrif” Jiru.
Alphari previously played for Misfits Gaming and has been with their League of Legends team since day one. He first played for the team in the UK scene back in 2016, when they played under the Renegades Banditos branding, before they found new owners and rebranded to Misfits.
After winning the ESL UK & Ireland Premiership, they then progressed to the EU Challenger Series and qualified for the EU LCS straight after. They also put in a solid performance in Worlds 2017, so very nearly causing an upset against then-reigning-champions SKT.
The news comes as fellow British teammate, jungler Nubar “Maxlore” Sarafian, signs a new three-year deal with Misfits.
He posted on Instagram: “Extremely happy to have re-signed with Misfits! Misfits is a fantastic organisation and has great values. Very excited to work with this organisation and roster for 2019. The future is looking bright.”
Misfits have also signed support player Kang “GorillA” Beom-hyeon, top-laner Paul “sOAZ” Boyer and mid-laner Fabian “Febiven” Diepstraten.
Maxlore and Alphari played together in the UK scene back in 2015 with Team Infused and reunited when Maxlore joined Misfits back in May 2017.
Alphari’s new team, Origen, has been acquired by Astralis’ parent company RFRSH Entertainment and has landed a spot in the new League of Legends European Championship (LEC), which was announced yesterday. This replaces the current EU LCS.
Origen will keep their founder and former pro player Enrique “xPeke” Cedeño Martínez on board, who will focus on fan engagement and content.
Image source: LoL Esports Flickr

Notify of
Inline Feedbacks
View all comments